Cargando…

Adherence to Asacol once daily versus divided regimen for maintenance therapy in ulcerative colitis: a prospective, multicenter, randomized study

BACKGROUND/AIMS: A once-daily (OD) regimen of 5-aminosalicylic acid (5-ASA) was easier to comply with than a divided daily (DD) regimen, and that treatment efficacy for ulcerative colitis (UC) was not affected by the dosing regimen. This study evaluated treatment adherence of OD and DD dosing in the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Soo-Kyung, Park, Sang Hyun, Eun, Chang Soo, Seo, Geom Seog, Im, Jong Pil, Kim, Tae Oh, Park, Dong-Il
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Association for the Study of Intestinal Diseases 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667373/ https://www.ncbi.nlm.nih.gov/pubmed/30727712 http://dx.doi.org/10.5217/ir.2018.00064

Ejemplares similares

One-year Investigator-blind Randomized Multicenter Trial Comparing Asacol 2.4 g Once Daily with 800 mg Three Times Daily for Maintenance of Remission in Ulcerative Colitis
por: Hawthorne, A Barney, et al.
Publicado: (2012)

2.4 g Mesalamine (Asacol 400 mg tablet) Once Daily is as Effective as Three Times Daily in Maintenance of Remission in Ulcerative Colitis: A Randomized, Noninferiority, Multi-center Trial
por: Suzuki, Yasuo, et al.
Publicado: (2017)

Protective Effect of Asacol in Combination with Pantoprazole in Ulcerative Colitis Patients Who Defecate Asacol Tablets Intactly: A Clinical Trial Study
por: Bashiri, Homayoon, et al.
Publicado: (2020)

Additive effect of probiotics (Mutaflor) on 5-aminosalicylic acid therapy in patients with ulcerative colitis
por: Park, Soo-Kyung, et al.
Publicado: (2022)

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
por: Kamm, M A, et al.
Publicado: (2008)

Among once-daily regimens, single tablet regimens (STRs) are associated with better adherence
por: Murri, R, et al.
Publicado: (2012)

Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis
por: Kedia, Prashant, et al.
Publicado: (2007)

Efficacy of sigmoidoscopy for evaluating disease activity in patients with ulcerative colitis
por: Park, Su Bum, et al.
Publicado: (2022)

Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine
por: Oliveira, Lilliana, et al.
Publicado: (2011)

Patient considerations in the management of ulcerative colitis: role of once-daily MMX mesalamine
por: Zandman, Daniel B, et al.
Publicado: (2009)

ONCE-DAILY VERSUS DIVIDED DOSAGE LITHIUM THERAPY IN ACUTE MANIA
por: Suresh, K.P., et al.
Publicado: (1995)

Potential Oral Microbial Markers for Differential Diagnosis of Crohn’s Disease and Ulcerative Colitis Using Machine Learning Models
por: Kang, Sang-Bum, et al.
Publicado: (2023)

Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis
por: Böhm, Stephan Karl, et al.
Publicado: (2014)

Is Clostridium difficile infection a real threat in patients with ulcerative colitis? A prospective, multicenter study in Korea
por: Kim, Dae Bum, et al.
Publicado: (2018)

Comparison of efficacies of once-daily dose multimatrix mesalazine and multiple-dose mesalazine for the maintenance of remission in ulcerative colitis: a randomized, double-blind study
por: Ogata, Haruhiko, et al.
Publicado: (2017)

Is once daily multimatrix mesalazine therapy effective regardless of the dose in patients with mild to moderate ulcerative colitis?
por: Jeon, Seong Ran
Publicado: (2018)

Clinical Features of Ulcerative Colitis in Korea
por: Park, Seon Mee, et al.
Publicado: (1996)

HIV virologic response better with single-tablet once daily regimens compared to multiple-tablet daily regimens
por: Kapadia, Shashi N, et al.
Publicado: (2018)

Once-daily dose regimen of ribavirin is interchangeable with a twice-daily dose regimen: randomized open clinical trial
por: Balk, Jiska M, et al.
Publicado: (2015)

Efficacy and safety of once daily versus twice daily mesalazine for mild-to-moderate ulcerative colitis: A meta-analysis of randomized controlled trials
por: Zheng, Xin, et al.
Publicado: (2019)

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study
por: Travis, Simon P L, et al.
Publicado: (2014)

Clinical Efficacy of Beclomethasone Dipropionate in Korean Patients with Ulcerative Colitis
por: Lee, Yoon Jee, et al.
Publicado: (2017)

Prognostic Value of Terminal Ileal Inflammation in Patients with Ulcerative Colitis
por: Yu, Jongwook, et al.
Publicado: (2021)

Twice-Daily versus Once-Daily Pramipexole Extended Release Dosage Regimens in Parkinson's Disease
por: Yun, Ji Young, et al.
Publicado: (2017)

Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis
por: Oh, Shin Ju, et al.
Publicado: (2021)

Second Korean guidelines for the management of ulcerative colitis
por: Choi, Chang Hwan, et al.
Publicado: (2017)

Adherence in ulcerative colitis: an overview
por: Testa, Anna, et al.
Publicado: (2017)

The use of a darunavir/ritonavir once-daily regimen in two pregnant women
por: Lambert, JS, et al.
Publicado: (2010)

Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial
por: Kruis, W, et al.
Publicado: (2009)

Comparison of Long-term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis
por: Lee, Yong Il, et al.
Publicado: (2021)

A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects
por: Dawra, Vikas Kumar, et al.
Publicado: (2019)

Model‐Informed Development and Registration of a Once‐Daily Regimen of Extended‐Release Tofacitinib
por: Lamba, M, et al.
Publicado: (2017)

Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study
por: Kim, Eun Hye, et al.
Publicado: (2015)

New approach of medicinal herbs and sulfasalazine mixture on ulcerative colitis induced by dextran sodium sulfate
por: Shin, Mi-Rae, et al.
Publicado: (2020)

Efficacy of Once Daily versus Divided Daily Administration of Low Daily Dosage (15 mg/Day) of Methimazole in the Induction of Euthyroidism in Graves' Hyperthyroidism: A Randomized Controlled Study
por: Sriussadaporn, Sutin, et al.
Publicado: (2017)

Development of a Machine Learning Model to Distinguish between Ulcerative Colitis and Crohn’s Disease Using RNA Sequencing Data
por: Park, Soo-Kyung, et al.
Publicado: (2021)

Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications
por: Kubitza, Dagmar, et al.
Publicado: (2016)

Factors associated with low adherence to oral 5-aminosalicylic acid in patients with ulcerative colitis
por: Lee, Jin, et al.
Publicado: (2019)

Omega-3 fatty acids in the maintenance of ulcerative colitis
por: Papadia, Cinzia, et al.
Publicado: (2010)

Annular Leukocytoclastic Vasculitis in a Patient with Ulcerative Colitis
por: Hong, Jong Soo, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_oe5uagpoi60dkr8a2o8278big5